BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 28825327)

  • 21. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
    Algeri M; Del Bufalo F; Galaverna F; Locatelli F
    Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Horibe K; Morris JD; Tuglus CA; Dos Santos C; Kalabus J; Anderson A; Goto H; Ogawa C
    Int J Hematol; 2020 Aug; 112(2):223-233. PubMed ID: 32564243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
    Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
    J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
    Halford Z; Coalter C; Gresham V; Brown T
    Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blinatumomab for the treatment of acute lymphoblastic leukemia.
    Kaplan JB; Grischenko M; Giles FJ
    Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting non-Hodgkin lymphoma with blinatumomab.
    Sanders S; Stewart DA
    Expert Opin Biol Ther; 2017 Aug; 17(8):1013-1017. PubMed ID: 28532177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
    J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
    Wolach O; Stone RM
    Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.
    Köhnke T; Krupka C; Tischer J; Knösel T; Subklewe M
    J Hematol Oncol; 2015 Oct; 8():111. PubMed ID: 26449653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
    Zugmaier G; Klinger M; Schmidt M; Subklewe M
    Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
    Stein A; Franklin JL; Chia VM; Arrindell D; Kormany W; Wright J; Parson M; Amouzadeh HR; Choudhry J; Joseph G
    Drug Saf; 2019 May; 42(5):587-601. PubMed ID: 30565020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
    Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
    Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
    Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
    Marini BL; Sun Y; Burke PW; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Jan; 24(1):67-73. PubMed ID: 27799606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.